Adverse Reactions to Dry Needling Therapy: Insights from Polish Physiotherapy Practice.

: The current study aimed to characterize the adverse reactions associated with dry needling (DN) treatments reported by Polish physiotherapists, with a secondary objective of investigating whether the level of DN experience influences the occurrence of these adverse effects. : A total of 102 Polish physiotherapists, all with regular DN practice, participated in an ad hoc online survey. The participants were categorized by their level of experience in DN treatment: 44 with 0-2 years, 43 with 3-6 years, and 15 with more than 7 years of experience. The survey consisted of 27 questions focused on both mild and severe adverse effects resulting from DN treatments. : The results showed that in the short term (over the past week), minor bleeding was the most commonly reported mild adverse effect (70%), followed closely by slightly pain during treatment (68%). Slight pain following treatment was also reported by 52% of respondents. No significant relationship was found between experience with dry needling (DN) and the reporting of mild adverse effects, with the exception of tingling (X = 10.958; = 0.004). In the retrospective analysis of the past month, most respondents reported experiencing bleeding between one and three times (49%), while bruising occurred one to three times in 44% of cases. Similarly, 44% of respondents noted pain after treatment one to three times, and 47% experienced pain during DN at this frequency. A significant interaction with DN experience was observed in the frequency of drowsiness reported over the past month (X = 19.735; = 0.032). : Severe adverse effects were extremely rare in clinical practice: pneumothorax and shock were each reported by 3% of respondents, nerve palsy by 14%, infection by 2%, and hospitalization by 1%. In conclusion, this study suggests that most adverse effects are mild, typically involving bleeding and slight pain during or after treatment. Additionally, DN experience does not appear to be a significant factor influencing the type or prevalence of these adverse effects.